Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients - Episode 1

Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

Elizabeth O’Donnell, MD, discusses the key considerations when choosing frontline therapy for transplant-ineligible patients with newly diagnosed multiple myeloma and how factors such as frailty, age, and performance status influence the decision-making process.

Now Viewing
EP. 1: Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients
EP. 2: Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials
EP. 3: Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy
EP. 4: Optimizing Regimens and Managing Adverse Events in TIE NDMM
EP. 5: Looking Ahead and Key Takeaways
EP. 6: Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients
EP. 7: Overview of PERSEUS, IsKia, and GMMG-HD7
EP. 8: Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM
  1. Please comment on the key considerations when choosing frontline therapy for transplant-ineligible patients with newly diagnosed multiple myeloma.
  2. How do patient factors such as frailty, age, and performance status influence your decision-making process?

Related Content:

Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients
Overview of PERSEUS, IsKia, and GMMG-HD7
Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM
Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients